For those interested, I found this May 2022 coverage update document from
BCBS of Mass.
____________________________________
"68Ga Prostate-specific membrane antigen (PSMA) PET/CT or
18F-DCFPyL (piflufolastat or Pylarify) PET/CT
Diagnostic Workup and Diagnosis: Not indicated
Management: Indicated when ALL of the following
criteria are met:
• Original clinical stage T1-T3 and NX or N0 treated with prostatectomy and/or radiation therapy, with biochemically recurrent/persistent disease
• Results of conventional imaging performed within the past 60 days are negative for metastasis
• Patient is a candidate for curative intent salvage therapy
• PSA level is > 1 ng/ml or PSA is rising
• PET/CT has not been performed within the past 3 months
Surveillance: Not indicated
Explanation of change • Addition of new prostate -specific membrane antigen (PSMA) PET/CT scenarios"
____________________________________
You can paste the URL; it isn't working as a link:
https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/999%20
Medical%20
Policy%20
Updates%20
prn.pdf
Post Edited (DjinTonic) : 5/22/2022 6:04:02 AM (GMT-6)